DNA polymerase theta emerges as a promising target for cancer therapy
DNA polymerase theta (Polθ) is overexpressed in many cancers and is essential for microhomology-mediated end joining, making it a novel therapeutic target.
Asset / Drug
Drug and asset intelligence for DNA with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Targeted Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.